Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066–78.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627–40.
   PubMed Web of Science ®Google Scholar
• Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868–78.
   PubMed Web of Science ®Google Scholar
• Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007;125:281–90.
   PubMed Web of Science ®Google Scholar
• Di SA, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, Peripheral regulatory T cells and serum transforming growth factor-beta: Relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:1891–7.
   PubMedGoogle Scholar
• Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 2010;43:325–33.
   PubMed Web of Science ®Google Scholar
• Kelsen J, Agnholt J, Hoffmann HJ, Romer JL, Hvas CL, Dahlerup JF. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol 2005;141:549–57.
   PubMed Web of Science ®Google Scholar
• Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004;173:3119–30.
   PubMed Web of Science ®Google Scholar
• Faubion WA, De Jong YP, Molina AA, Ji H, Clarke K, Wang B, Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology 2004;126:1759–70.
   PubMedGoogle Scholar
• Kaser A, Blumberg RS. The other way round: colitis regulates regulatory T cells. Gastroenterology 2004;126:1903–6.
   PubMedGoogle Scholar
• Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33–9.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277–85.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De HG, Vermeire S, Noman M, Bullens D, Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299–310.
   PubMed Web of Science ®Google Scholar
• Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008;125:178–83.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Nancey S, Sardi F, Roblin X, Flourie B, Kaiserlian D. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:160–70.
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345–54.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69:3995–4000.
   PubMedGoogle Scholar
• Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925–7.
   PubMed Web of Science ®Google Scholar
• Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983–90.
   PubMed Web of Science ®Google Scholar
• Aerts NE, Dombrecht EJ, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell Immunol 2008;251:109–15.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304–10.
   PubMed Web of Science ®Google Scholar
• Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert-Margolis V, Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom 2009;76:69–78.
   PubMedGoogle Scholar
• Law JP, Hirschkorn DF, Owen RE, Biswas HH, Norris PJ, Lanteri MC. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytometry A 2009;75:1040–50.
   PubMed Web of Science ®Google Scholar
• Presicce P, Moreno-Fernandez ME, Lages CS, Orsborn KI, Chougnet CA. Association of two clones allows for optimal detection of human FOXP3. Cytometry A 2010;77:571–9.
   PubMedGoogle Scholar
• Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 2008;16:194–202.
   PubMed Web of Science ®Google Scholar
• Hardenberg G, Steiner TS, Levings MK. Environmental influences on T regulatory cells in inflammatory bowel disease. Semin Immunol 2011;23:130–8.
   PubMed Web of Science ®Google Scholar